Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) was up 3.2% on Friday . The stock traded as high as $0.96 and last traded at $0.96. Approximately 263,496 shares were traded during trading, an increase of 3% from the average daily volume of 256,898 shares. The stock had previously closed at $0.93.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on ONCY shares. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Thursday, November 14th. Leede Financial downgraded shares of Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a research report on Wednesday, November 13th. Finally, Raymond James upgraded shares of Oncolytics Biotech to a "moderate buy" rating in a research note on Thursday, November 14th.
View Our Latest Analysis on ONCY
Oncolytics Biotech Price Performance
The business's 50-day moving average price is $0.97 and its 200-day moving average price is $1.01. The firm has a market capitalization of $74.35 million, a PE ratio of -3.56 and a beta of 1.63.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
